Related Experiment Videos
Molecular risk stratification in advanced heart failure patients
Guillaume Lamirault1, Nolwenn Le Meur, Jean-Christian Roussel
1Inserm, U915, Nantes, France.
Journal of Cellular and Molecular Medicine
|October 2, 2009
Summary
Cardiac gene expression profiling accurately distinguishes heart failure (HF) severity. This molecular risk stratification, using left (LV) and right (RV) ventricle samples, aids in personalized treatment strategies for advanced HF patients.
Area of Science:
- Cardiology
- Molecular Biology
- Genomics
Background:
- Risk stratification is vital for managing advanced heart failure (HF).
- Personalized therapeutic strategies, including heart transplantation and ventricular assist device (VAD) implantation, depend on accurate HF severity assessment.
- Current methods for HF risk stratification require improvement for better patient management.
Purpose of the Study:
- To investigate if cardiac gene expression profiling can differentiate between HF patients of varying disease severity.
- To identify molecular predictors of HF severity using gene expression data from ventricular tissue.
- To assess the utility of both left ventricle (LV) and right ventricle (RV) samples for molecular risk stratification.
Main Methods:
- Gene expression profiling was performed on LV and RV tissue samples from 44 advanced HF patients undergoing cardiac transplantation or VAD placement.
- An in-house microarray with 4217 muscular organ-relevant genes was utilized.
- Statistical analysis identified gene expression signatures distinguishing between HF patients classified as deteriorating, intermediate, or stable.
Main Results:
- A 170-gene predictor for LV and a 129-gene predictor for RV were identified, differentiating between stable and deteriorating HF.
- The LV predictor achieved high sensitivity (88-92%) and specificity (96-100%) for HF severity.
- The RV predictor demonstrated excellent sensitivity (96-100%) and specificity (100%) for HF severity, showing comparable predictive power to LV samples.
- Molecular predictions were reproducible across biological replicates.
Conclusions:
- Cardiac gene expression profiling can reliably identify patients with the highest heart failure severity.
- Both LV and RV tissue samples are suitable for molecular risk stratification in advanced HF.
- This gene expression-based approach offers a sensitive and specific method for HF risk assessment, potentially guiding therapeutic decisions.
Related Concept Videos
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...